About Sevodyne2020-04-22T09:28:49+00:00


About Sevodyne

Welcome to sevodyne.co.uk

Sevodyne (buprenorphine) transdermal patches are indicated for the treatment of non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia.1

Available as:

  • Transdermal patch 5 microgram/hr

  • Transdermal patch 10 microgram/hr

  • Transdermal patch 20 microgram/hr

Sevodyne transdermal patches are bioequivalent to Norspan®  (buprenorphine) (Mundipharma GmbH, Germany)/BuTrans® (buprenorphine) (Napp Pharmaceuticals Ltd, UK) buprenorphine transdermal patches.2

Sevodyne could offer significant cost savings to your practice and clinical commissioning group (CCG).3*

Buprenorphine 5 microgram/hr, 10 microgram/hr and 20 microgram/hr transdermal patches are in category C of the UK Drug Tariff.3

However, the NHS could make 69% savings on the cost of category C buprenorphine patches by prescribing Sevodyne by brand name.3*

Quite simply a wholesale switch of buprenorphine transdermal patches 5µg/hr, 10µg/hr and 20µg/hr prescriptions to Sevodyne could still save an average CCG £58,592 per year.4**

Sevodyne extends the existing Category C Cost-saving Prolonged-release Product Portfolio from Aspire Pharma.

In addition with Sevodyne you can get:

  • Pricing not dependent on competitor activity***

  • Price guaranteed***

*Based on 69% saving on the cost of Category C buprenorphine transdermal patches in the UK Drug Tariff.  ** Savings based on market data in reference 4. Savings calculated from 2019 spend of 218 CCGs switching their generic and originator brand 5, 10 and 20mcg buprenorphine transdermal patch prescriptions to Sevodyne. ***No change in price subject to no material change to the products or Category C of the UK Drug Tariff until the 2024 PPRS review.
References: 1) Sevodyne SmPCs.  2) Data on file, 1010067149 v 4.0 October 2019.  3) April 2020 UK Drug Tariff.  4) epact data Jan 2019 – Jan 2020 (UK).


For further information please call: 01730 231148,
email: info@aspirepharma.co.uk or visit www.aspirepharma.co.uk
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148

For more information about Sevodyne, please see the abbreviated prescribing information.

Revision reference – Sevodyne_8_16.04.2020

More products available
in this range:
Click to view their
individual websites